Research-use reference. This page explains the science of GLP-1 class peptides for buyers and researchers. It is educational and does not provide medical advice or dosing guidance. Approved GLP-1 medicines are prescription drugs; their use is a matter for a licensed clinician. All material WUMO supplies is for research and laboratory use only.
Quick answer. GLP-1 peptides work as receptor agonists: they imitate a natural gut hormone (GLP-1) and switch on its receptor, which supports glucose-dependent insulin response and reduces appetite by slowing gastric emptying and acting on appetite signaling. Newer molecules add more receptor targets — semaglutide acts on GLP-1 alone, tirzepatide on GIP + GLP-1, and retatrutide on GIP + GLP-1 + glucagon. They are engineered peptides (31–39 amino acids) with a fatty-acid chain that extends how long they last, not short "mini" peptides.
If you evaluate or source these molecules but don't have a chemistry or pharmacology background, the marketing language — "agonist," "incretin," "single vs triple," "31-mer" — can be confusing. This article explains what is actually happening at the molecular level, in plain language. It does not tell anyone how to use these molecules; it explains how they work.
Definition. A GLP-1 receptor agonist is an engineered peptide that activates the glucagon-like peptide-1 (GLP-1) receptor — a key node in glucose-dependent insulin signaling and appetite regulation. Newer molecules also activate the GIP receptor and/or the glucagon receptor, making them dual or triple receptor agonists rather than pure GLP-1 agonists.
What is a GLP-1 receptor agonist? (peptide = a signal, not a foreign drug)
Your cells are covered in receptors — molecular "locks." Your body makes its own signaling molecules ("keys") that fit those locks and tell a cell what to do: release insulin, slow digestion, reduce hunger.
A therapeutic peptide is essentially a purpose-built key. That gives two basic modes:
- Agonist — the peptide fits the lock and turns it, doing the job the natural signal would do (or replacing a signal the body is short of).
- Antagonist — the peptide fits the lock but blocks it, so the body's own signal can't get in.
GLP-1 class molecules are agonists: they imitate the natural gut hormone GLP-1 and activate its receptor. That is why documentation calls them "GLP-1 receptor agonists," not simply "GLP-1."
What GLP-1 receptor agonists actually do
GLP-1 (glucagon-like peptide-1) is an incretin — a hormone the gut releases after eating. Activating its receptor has two well-documented effects relevant to metabolic research [Campbell & Drucker, 2013]:
- It supports a glucose-dependent insulin response (helping the body handle sugar).
- It acts on appetite and gastric emptying — reducing hunger signals and slowing how fast the stomach empties.
That second effect is why this class became central to obesity research. The molecule is not "burning fat" directly — it changes the appetite and digestion signals.
What happens to a peptide in the body
Two different questions get mixed up here, so it's worth separating them.
Where do the side effects come from? The familiar effects of approved GLP-1 medicines — nausea and other gastrointestinal effects — are mechanism-based: they follow from activating the GLP-1 receptor itself (including effects on gut motility and appetite signaling). Pharmacological effect is determined by receptor activation, not by how the molecule is later degraded. These effects are well-characterized in the approved labels, and human dosing is strictly a clinical decision.
What happens to the molecule afterwards? Peptides are eventually cleaved by enzymes into ordinary amino acids — the same building blocks the body uses every day. That fact matters mostly for a different question: a weakly-binding, incomplete impurity fragment in a raw material tends to be degraded rather than to persist. That is a point about evaluating sequence-related impurities (see sourcing notes below) — not an explanation for the drug's side-effect profile.
What "generations" mean: single → dual → triple agonist
Semaglutide, tirzepatide and retatrutide are often lumped together as "GLP-1." Scientifically they differ by how many receptors the peptide is designed to activate:
| Molecule | Receptor profile | Amino acids | Regulatory status |
|---|---|---|---|
| Semaglutide | GLP-1 only (single agonist) | 31 | Approved (Ozempic / Wegovy / Rybelsus) |
| Tirzepatide | GIP + GLP-1 (dual agonist) | 39 | Approved (Mounjaro / Zepbound) |
| Retatrutide | GIP + GLP-1 + glucagon (triple agonist) | 39 | Investigational — in Phase 3 trials as of 2026 (not approved) |
A crucial correction to a widespread myth: the "generations" do not come from the peptides being different lengths of tiny chains. Each is a sizeable, engineered molecule carrying sequence modifications and a fatty-acid chain that extends how long it lasts in the body. The advance from one generation to the next is about which and how many receptors are engaged — not "a few more amino acids." (For reference, a Phase 2 clinical study of retatrutide, the triple agonist, reported mean body-weight reductions of up to ~24% at 48 weeks [Jastreboff et al., NEJM 2023].)
For the procurement-side comparison — regulatory status, what to verify on a COA before ordering — see our companion reference: GLP-1, GIP & Glucagon Peptides: a B2B Sourcing Reference.
Route of administration changes the whole picture
How a peptide enters the body changes how much of it reaches circulation — and that depends on formulation technology, not a fixed linear scale. For the GLP-1 class specifically:
- Subcutaneous injection is the established route for the injectable products, and is efficient.
- Oral delivery is intrinsically hard: peptides are digested and poorly absorbed, so systemic exposure stays low without an absorption enhancer. Oral semaglutide (Rybelsus) reaches only on the order of ~1% bioavailability and relies on a co-formulated enhancer (SNAC) that protects the peptide and helps it cross the gut wall — it is not simply an enteric-coated pill.
- Intravenous dosing (near-complete systemic availability) is essentially a research / clinical-study context, not how these products are used.
This is why "same peptide, different format" is not a small detail: an oral and an injectable version of the same molecule are engineered very differently — something to confirm against the specification and COA for the exact format you are evaluating.
What matters when sourcing GLP-1 class peptides
If you are evaluating raw material rather than a finished drug, the science above turns into a short verification checklist:
- Sequence / amino-acid count — confirm 31 (semaglutide) vs 39 (tirzepatide, retatrutide); a mismatch signals the wrong molecule.
- Lipid modification — the fatty-acid chain is part of the molecule's identity, not an optional extra.
- Receptor profile — single vs dual vs triple should be stated explicitly, not hidden under "GLP-1 class."
- Analytical consistency — HPLC (purity) and LC-MS (molecular-weight identity) should agree, on the specific batch you receive.
We cover these in depth in the companion B2B references: GLP-1, GIP & Glucagon Peptides — Sourcing Reference and How to read a peptide COA (HPLC / LC-MS).
Frequently asked questions
Is a GLP-1 peptide the same as a "fat-burning" drug? No. It does not burn fat directly. It is a receptor agonist that imitates a natural gut hormone, changing appetite and glucose-handling signals; the effect studied in obesity research follows from that signaling change.
What does "GLP-1 receptor agonist" mean? It means the peptide binds and activates the GLP-1 receptor — the same lock the body's own GLP-1 hormone uses — switching it on (agonist) rather than blocking it (antagonist).
Are semaglutide, tirzepatide and retatrutide all "GLP-1"? Only semaglutide is a pure GLP-1 agonist. Tirzepatide is a GIP/GLP-1 dual agonist; retatrutide is a GIP/GLP-1/glucagon triple agonist. "GLP-1 class" is a convenient umbrella, but precise documentation should state the exact receptor profile.
Are these short 4–8 amino-acid peptides? No — a common misconception. Semaglutide is 31 amino acids; tirzepatide and retatrutide are 39, each with a fatty-acid chain. The differences come from sequence modification and receptor targeting, not chain length.
Where do GLP-1 side effects come from? They are mechanism-based — they follow from activating the GLP-1 receptor (effects on gut motility and appetite signaling), not from how the peptide is later broken down. Gastrointestinal effects such as nausea are the ones commonly listed in approved labels; human dosing is a clinical decision.
Is retatrutide approved? No. As of 2026 it is an investigational molecule in Phase 3 trials and is not FDA-approved. Its regulatory status should be treated as distinct from approved molecules.
Sources
- Campbell JE, Drucker DJ. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 2013. PMID 23684623.
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. DOI 10.1056/NEJMoa2301972; PMID 37366315.
- FDA Prescribing Information (via DailyMed): semaglutide (Ozempic / Wegovy / Rybelsus, Novo Nordisk); tirzepatide (Mounjaro / Zepbound, Eli Lilly).
Disclaimer. Provided for scientific and educational reference and for research-use buyers. Not medical advice; does not describe how to use any substance in humans. Approved GLP-1 medicines are prescription-only — consult a licensed healthcare professional. Materials referenced are supplied for laboratory and research use only.